Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1992;1(6):391–395. doi: 10.1155/S0962935192000590

Receptor mechanisms of PAF mediated lymphatic constriction in the canine forelimb

D E Dobbins 1
PMCID: PMC2365367  PMID: 18475490

Abstract

Platelet activating factor (PAF) is a potent inflammatory lipid. In this study we assessed the ability of PAF to impact lymphatic vessel function by altering prenodal lymphatic resistance. Intralymphatic PAF (7.47 × 10−6, 7.47 × 10−5 and 7.47 × 10−4 M) increased lymphatic perfusion pressure at the two highest infusion rates. PAF mediated lymphatic constriction was not altered by the intra-arterial infusion of phentolamine but was blocked by the intra-arterial infusion of the PAF receptor antagonist WEB 2170. These data indicate that in addition to PAF's effects on microvascular permeability, this agent may also impact the ability of the lymphatics to transport fluid through alterations in lymphatic smooth muscle tone. PAF mediated lymphatic constriction is not mediated by α-receptors but rather through PAF receptor mediated mechanism.

Full Text

The Full Text of this article is available as a PDF (473.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benveniste J., Henson P. M., Cochrane C. G. Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med. 1972 Dec 1;136(6):1356–1377. doi: 10.1084/jem.136.6.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Benveniste J. Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils. Nature. 1974 Jun 7;249(457):581–582. doi: 10.1038/249581a0. [DOI] [PubMed] [Google Scholar]
  3. Björk J., Lindbom L., Gerdin B., Smedegård G., Arfors K. E., Benveniste J. Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. Acta Physiol Scand. 1983 Nov;119(3):305–308. doi: 10.1111/j.1748-1716.1983.tb07343.x. [DOI] [PubMed] [Google Scholar]
  4. Dabney J. M., Buehn M. J., Dobbins D. E. Perfused prenodal lymphatics are constricted by prostaglandins. Am J Physiol. 1991 Jan;260(1 Pt 2):H1–H5. doi: 10.1152/ajpheart.1991.260.1.H1. [DOI] [PubMed] [Google Scholar]
  5. Dobbins D. E., Buehn M. J., Dabney J. M. Constriction of perfused lymphatics by acetylcholine, bradykinin and histamine. Microcirc Endothelium Lymphatics. 1990 Dec;6(6):409–425. [PubMed] [Google Scholar]
  6. Dobbins D. E., Buehn M. J., Dabney J. M. The inflammatory actions of platelet activating factor are blocked by levorotatory terbutaline. Microcirc Endothelium Lymphatics. 1990 Dec;6(6):437–455. [PubMed] [Google Scholar]
  7. Dobbins D. E. Catecholamine-mediated lymphatic constriction: involvement of both alpha 1- and alpha 2-adrenoreceptors. Am J Physiol. 1992 Aug;263(2 Pt 2):H473–H478. doi: 10.1152/ajpheart.1992.263.2.H473. [DOI] [PubMed] [Google Scholar]
  8. Dobbins D. E., Dabney J. M. Endothelin-mediated constriction of prenodal lymphatic vessels in the canine forelimb. Regul Pept. 1991 Jul 23;35(1):81–91. doi: 10.1016/0167-0115(91)90256-g. [DOI] [PubMed] [Google Scholar]
  9. Dobbins D. E. Neuropeptide modulation of lymphatic smooth muscle tone in the canine forelimb. Mediators Inflamm. 1992;1(4):241–246. doi: 10.1155/S096293519200036X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Felix S. B., Steger A., Baumann G., Busch R., Ochsenfeld G., Berdel W. E. Platelet-activating factor-induced coronary constriction in the isolated perfused guinea pig heart and antagonistic effects of the PAF antagonist WEB 2086. J Lipid Mediat. 1990 Jan-Feb;2(1):9–20. [PubMed] [Google Scholar]
  11. Iñarrea P., Alonso F., Sanchez-Crespo M. Platelet-activating factor: an effector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse. Immunopharmacology. 1983 Jun;6(1):7–14. doi: 10.1016/0162-3109(83)90011-5. [DOI] [PubMed] [Google Scholar]
  12. Klee A., Schmid-Schönbein G. W., Seiffge D. Effects of platelet activating factor on rat platelets in vivo. Eur J Pharmacol. 1991 Dec 17;209(3):223–230. doi: 10.1016/0014-2999(91)90173-n. [DOI] [PubMed] [Google Scholar]
  13. Ma X. L., Weyrich A. S., Krantz S., Lefer A. M. Mechanisms of the cardioprotective actions of WEB-2170, bepafant, a platelet activating factor antagonist, in myocardial ischemia and reperfusion. J Pharmacol Exp Ther. 1992 Mar;260(3):1229–1236. [PubMed] [Google Scholar]
  14. Vemulapalli S., Chiu P. J., Barnett A. Cardiovascular and renal action of platelet-activating factor in anesthetized dogs. Hypertension. 1984 Jul-Aug;6(4):489–493. doi: 10.1161/01.hyp.6.4.489. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES